0

Hydraderm for Male Pattern Baldness

IW
Overseen ByIrmina Wallander
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Minnesota
Must be taking: Alopecia treatments
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

The study will be focused on evaluating the use of hydradermabrasion on the scalp. The study aims to assess the effect of this treatment on scalp health and hair growth.

Do I have to stop taking my current medications?

No, you must continue your current treatment for androgenetic alopecia throughout the study without any changes.

What safety data exists for Hydraderm treatment for male pattern baldness?

The provided research does not contain specific safety data for Hydraderm, Venus Glow, or Hydradermabrasion treatments for male pattern baldness. The studies focus on other topics such as hirsutism, cosmetics and cancer, minoxidil for alopecia, alpha hydroxy acids in cosmetics, and general cosmetic safety. Therefore, no relevant safety data for Hydraderm treatment is available in the provided research.12345

Is the treatment Venus Glow a promising treatment for male pattern baldness?

The information provided does not directly address the effectiveness of Venus Glow for male pattern baldness. The articles focus on other treatments and conditions, so we can't conclude that Venus Glow is a promising treatment for this condition based on the given data.678910

What data supports the idea that Hydraderm for Male Pattern Baldness is an effective treatment?

The available research does not provide specific data on the effectiveness of Hydraderm for Male Pattern Baldness. Instead, it discusses other treatments like oral dutasteride, which showed improvement in 90% of patients, and TRICHOBIOLIGHT, which had excellent to good outcomes in 82.5% of patients. Without specific data on Hydraderm, it's unclear how it compares to these treatments.1112131415

Who Is on the Research Team?

RF

Ronda Farah, MD

Principal Investigator

University of Minnesota

Are You a Good Fit for This Trial?

This trial is for men and women aged 18-65 with male pattern baldness who can consent to the study, follow instructions, attend visits, be photographed without identity concealment, and maintain their current hair loss treatment. Excluded are those with scalp conditions/infections/cancers, autoimmune or blood disorders, recent scalp procedures, immunosuppression, non-English speakers or pregnant/breastfeeding individuals.

Inclusion Criteria

Participants who agree to be photographed for research purposes and their identity may not be concealed in these photographs.
I agree to not change my current hair loss treatment during the study.
I understand the study, can follow instructions, and will attend all required visits.
See 5 more

Exclusion Criteria

I am on immunosuppressive therapy.
Participants who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy
Non-English speakers
See 13 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive hydradermabrasion treatment on the scalp to improve scalp health and hair growth

16 weeks
4 sessions at 1-week intervals, followed by 3 sessions each 4 weeks apart

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
1 follow-up visit

What Are the Treatments Tested in This Trial?

Interventions

  • Venus Glow
Trial Overview The trial tests hydradermabrasion (Venus Glow) on the scalp to evaluate its effects on scalp health and hair growth in individuals with androgenic alopecia. Participants will receive this non-invasive treatment while continuing their existing hair loss treatments.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention

Venus Glow is already approved in United States, Canada for the following indications:

🇺🇸
Approved in United States as Venus Glow for:
🇨🇦
Approved in Canada as Venus Glow for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Minnesota

Lead Sponsor

Trials
1,459
Recruited
1,623,000+

Published Research Related to This Trial

Oral dutasteride (OD) is an effective treatment for male androgenetic alopecia, with 90% of patients showing improvement after 12 months of treatment, particularly in those receiving it as monotherapy.
The safety profile of OD is favorable, with only 2.6% of patients experiencing adverse effects, which resolved after discontinuation of the drug, and no adverse effects reported in those on low doses.
Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study.Vañó-Galván, S., Saceda-Corralo, D., Moreno-Arrones, OM., et al.[2020]
A 46-year-old woman with androgenic alopecia showed significant improvement after switching from finasteride to dutasteride, a different 5-reductase inhibitor, after 6 months of treatment.
Dutasteride was effective in this case without any observed side effects, suggesting it could be a promising alternative for treating androgenic alopecia, especially in patients who do not respond to other treatments.
Effective treatment of female androgenic alopecia with dutasteride.Olszewska, M., Rudnicka, L.[2015]
The new hair-lifting technique for treating male-pattern alopecia involves removing segments of bald skin and lifting existing hair into the bald areas, which can also provide a partial face-lift benefit.
This procedure is performed in stages under local anesthesia and is particularly effective for specific types of baldness, such as tonsure baldness in men and skull-cap androgenic alopecia in women.
Obliteration of alopecia by hair-lifting: a new concept and technique.Blanchard, G., Blanchard, B.[2018]

Citations

Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study. [2020]
Effective treatment of female androgenic alopecia with dutasteride. [2015]
Obliteration of alopecia by hair-lifting: a new concept and technique. [2018]
Trichobiolight: A new, effective protocol in the treatment of androgenetic alopecia and telogen effluvium. [2021]
Hair loss. What causes it and what can be done about it. [2019]
Interventions for Hirsutism. [2018]
Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration. [2023]
Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). [2023]
Are cosmetics based on alpha hydroxy acids safe to use when purchased over the internet? [2022]
Cosmetovigilance survey: are cosmetics considered safe by consumers? [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Laser and Light-Based Aesthetics in Men. [2015]
12.United Statespubmed.ncbi.nlm.nih.gov
Male pattern baldness. [2013]
13.United Statespubmed.ncbi.nlm.nih.gov
Scrotal Rejuvenation. [2020]
Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. [2013]
15.United Statespubmed.ncbi.nlm.nih.gov
New advances in the treatment of hypogonadism in the aging male. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security